12 June 2024 : Database Analysis
Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease
Hsin Hsiang Huang1DE, Yun-Yi Chen23BCD, Yu-Wei Fang14ADG, Hung-Hsiang Liou5AD, Jing-Tong Wang1B, Ming-Hsein Tsai14ADE*DOI: 10.12659/MSM.944314
Med Sci Monit 2024; 30:e944314
Table 5 Comparative stepwise multivariable analysis of febuxostat versus allopurinol.
| Outcomes | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| All-cause hospitalization | 1.33 (1.24–1.41) | <0.001 | 1.33 (1.25–1.41) | <0.001 | 1.33 (1.25–1.42) | <0.001 |
| Hospitalization for heart failure | 1.60 (1.42–1.81) | <0.001 | 1.59 (1.41–1.80) | <0.001 | 1.62 (1.43–1.83) | <0.001 |
| Hospitalization for cardiovascular intervention | 1.52 (1.32–1.74) | <0.001 | 1.51 (1.32–1.73) | <0.001 | 1.51 (1.32–1.74) | <0.001 |
| Model 1 represents a basic analysis following propensity score matching (sex, age, and Charlson comorbidity index) that pairs the febuxostat group and the allopurinol group in a 1: 1 ratio. Multivariable model 2 comprises model l as well as adjustments for comorbidities, including hypertension, ischemic heart disease, congestive heart failure, atrial fibrillation, peripheral vascular disease, stroke, hyperlipidemia, calculus of kidney, and cirrhosis. Multivariable model 3 comprises model 2 as well as adjustments for medications of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blocker, calcium channel blockers, antithrombotic agents, non-steroidal anti-inflammatory drug, fenofibrate, statin, and diuretic. HR – hazard ratio; CI – confidence interval. | ||||||